AMPH Q3 2025 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$192M+1.6% YoY

Gross Profit

$99M51.4% margin

Operating Income

$25M13.2% margin

Net Income

$17M9.0% margin

EPS (Diluted)

$0.37

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

$53M

Free Cash Flow

$47M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$889M

Stockholders' Equity

$777M

Cash & Equivalents

$217M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$192M	$189M	+1.6%
Gross Profit	$99M	$102M	-3.2%
Operating Income	$25M	$57M	-55.6%
Net Income	$17M	$40M	-57.1%

Revenue Segments

Total product revenues, net

$192M50%

Other Products

$64M17%

BAQSIMI

$54M14%

Primatene MIST

$29M8%

Epinephrine

$19M5%

Glucagon

$14M4%

Lidocaine

$13M3%

Geographic Segments

UNITED STATES

$180M94%

FRANCE

$10M5%

CHINA

$2M1%